Halozyme Therapeutics (HALO) Tops Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $103.00 +4.40%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.21), $0.07 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $39 million versus the consensus estimate of $38.37 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
